Reactogenicity and immunogenicity of a double-strength acellular pertussis vaccine.
The reactogenicity and immunogenicity of a double-strength acellular pertussis vaccine were evaluated after administration to 16 4-6-year-old children. The vaccine contained toxoided lymphocytosis-promoting factor (6.0 micrograms/dose), filamentous haemagglutinin (70 micrograms/dose), agglutinogens (1.4 micrograms/dose) and the 69 kDa protein (approximately 8.0 micrograms/dose). The vaccine was extremely well tolerated with few minor side effects following immunization. Significant increases in antibodies to all pertussis vaccine components were noted. In summary, this double-strength acellular pertussis vaccine, containing a very high dose of filamentous haemagglutinin, had minimal reactogenicity and was immunogenic. These findings, as well as other studies with this vaccine, indicate that filamentous haemagglutinin is not a major determinant of vaccine reactogenicity.
Blumberg
D A
DA
Department of Pediatrics, UCLA School of Medicine.
Chatfield
P C
PC
Cherry
J D
JD
Robinson
R G
RG
Smith
K
K
Mabie
L
L
Holroyd
H J
HJ
Baker
L R
LR
Dudenhoeffer
F E
FE
Apau
N
N
D000907:Antibodies, Bacterial / Q000096:biosynthesis; D001886:Bordetella pertussis / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D010567:Pertussis Vaccine / Q000009:adverse effects / Q000276:immunology / Q000302:isolation & purification*
D000907:Antibodies, Bacterial; D010567:Pertussis Vaccine